(IN BRIEF) In the Phase 3 IsKia trial presented at the American Society of Hematology (ASH) Annual Meeting, Sarclisa® (isatuximab)…
(IN BRIEF) The Phase 3 IMROZ trial, assessing the use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide, and…